Skip to contentG
Guided Therapeutics Inc
G
GTHPGuided Therapeutics Inc Q4 2023 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$32.00K$32.00Kderived— vs Q4 2022 Net Income-$386.00K-$386.00KderivedN/M vs Q4 2022 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Guided Therapeutics Inc · CIK 924515 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Gross Profitderived$16,000N/M Operating Incomederived-$486,000N/M Operating Cash Flowderived-$336,000N/M Free Cash Flowderived-$336,000N/M Margins · derivedGross margin50.0%
Operating margin-1518.8%
Net margin-1206.3%
ended Dec 31, 2023 · filed Mar 28, 2024 · 88 d after period end